Ardelyx announced that additional data supporting IBSRELA will be presented at the 2024 Digestive Disease Week Conference, DDW, to be held May 18-21, 2024, in Washington, D.C. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation, IBS-C, in adults.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
- Ardelyx price target raised to $12 from $11 at TD Cowen
- Ardelyx price target raised to $14.50 from $13.50 at Ladenburg
- Ardelyx price target raised to $14 from $13 at Citi
- Ardelyx reports Q1 EPS (11c), consensus (15c)